Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Manitoba

$27,000.00

Development of an adult mental health pharmacogenomic counselling tool for Canadian healthcare professionals

FY 2025-26

Summary
Pharmacogenomics (PGx) is the study of using genetic information to predict the likelihood of efficacy and/or toxicity of a drug in an individual. Mental health treatment often begins with trial-and-error prescribing, which can lead to frustrating medication failures, harmful side effects, and long delays in recovery. PGx-guided treatment has been shown to significantly increase the chance of symptom remission and reduce harmful side effects and hospitalizations by up to 40%. Additionally, it has shown economic benefits, projected to save Canadian healthcare systems billions of dollars. Despite these benefits, PGx is not yet routine as healthcare providers lack the standardized tools needed to interpret results and confidently discuss complex genetic information with their patients. Genetic counsellors are central to managing these complex conversations, yet PGx often falls outside traditional genetics clinics. Our research addresses this gap by developing a frontline tool for Canadian clinicians. It will translate complex genetic data into practical, stepwise guidance for patient education, informed consent, and medication management. Structured feedback will be gathered from an interdisciplinary group of Canadian experts (pharmacists, genetic counsellors, and PGx specialists) to ensure practicality and applicability. Ultimately, this work will help reduce medication guesswork, improve patient safety, and lead to more effective mental health care across Canada and lay the groundwork for future interdisciplinary collaboration between pharmacists and genetic counsellors. This tool will serve as the foundation for future research investigating its impact on patient outcomes informing the development of sophisticated real-time digital PGx clinical decision support tools.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572549
Name
Smith Samantha A
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of an adult mental health pharmacogenomic counselling tool for Canadian healthcare professionals
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Clinical Tool; Genetic Counselling; Mental Health; Pharmacogenomics; Psychotropic Medication; Testing
Abstract
Pharmacogenomics (PGx) is the study of using genetic information to predict the likelihood of efficacy and/or toxicity of a drug in an individual. Mental health treatment often begins with trial-and-error prescribing, which can lead to frustrating medication failures, harmful side effects, and long delays in recovery. PGx-guided treatment has been shown to significantly increase the chance of symptom remission and reduce harmful side effects and hospitalizations by up to 40%. Additionally, it has shown economic benefits, projected to save Canadian healthcare systems billions of dollars. Despite these benefits, PGx is not yet routine as healthcare providers lack the standardized tools needed to interpret results and confidently discuss complex genetic information with their patients. Genetic counsellors are central to managing these complex conversations, yet PGx often falls outside traditional genetics clinics. Our research addresses this gap by developing a frontline tool for Canadian clinicians. It will translate complex genetic data into practical, stepwise guidance for patient education, informed consent, and medication management. Structured feedback will be gathered from an interdisciplinary group of Canadian experts (pharmacists, genetic counsellors, and PGx specialists) to ensure practicality and applicability. Ultimately, this work will help reduce medication guesswork, improve patient safety, and lead to more effective mental health care across Canada and lay the groundwork for future interdisciplinary collaboration between pharmacists and genetic counsellors. This tool will serve as the foundation for future research investigating its impact on patient outcomes informing the development of sophisticated real-time digital PGx clinical decision support tools.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Smith, Samantha A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~